CANTA Share Price Performance
SEK 4.04
2.24 (124.79%)
61.6% undervalued intrinsic discount
SEK 10.50
Fair Value
Price SEK 4.04
AnalystConsensusTarget SEK 10.50
Fair ValueSEK 10.50
Share Pricen/a
Cantargia AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
CANTA Community Narratives
AN
Fair Value SEK 10.5 61.6% undervalued intrinsic discount
IL1RAP Platform Advancements And Strong Cash Runway Will Support Long Term Biotech Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
IL1RAP Platform Advancements And Strong Cash Runway Will Support Long Term Biotech Upside
Catalysts About Cantargia Cantargia is a biotech company developing IL1RAP targeted antibodies for oncology and inflammatory or autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 10.5
61.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-69.02% p.a.
Profit Margin
17.99%
Future PE
2.25kx
Price in 2028
SEK 6.8
Trending Discussion
Recently Updated Narratives
AN
IL1RAP Platform Advancements And Strong Cash Runway Will Support Long Term Biotech Upside
Fair Value: SEK 10.5 61.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cantargia AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 20, 2026
- 0.56
- 100.00%
- 45.33%
- 0%
About CANTA
- Founded
- 2009
- Employees
- 23
- CEO
- WebsiteView website
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V. and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
